Rallybio receives $50M termination fee after Candid merger terminates for UCB deal

Rallybio Corp

Candid Therapeutics terminated its merger with Rallybio to enter a Permitted Alternative Agreement with UCB S.A.
Rallybio entitled to $50,000,000 Parent Termination Fee plus $375,000 expense reimbursement, payable by May 4, 2026.
Rallybio, Candid and UCB entered a waiver releasing claims and waiving certain merger rights.
Rallybio intends to withdraw its Form S-4 registration statement filed for the merger.
The termination fee provides immediate cash, but the merger failure is a setback for Rallybio's strategic plan.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rallybio Corp terminated Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. valued at $50,000,000 Parent Termination Fee (effective 2026-05-03).

Action: termination
Agreement: merger
Counterparty: Candid Therapeutics, Inc.
Value: $50,000,000 Parent Termination Fee
Effective: 2026-05-03

Exact text from the filing

On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the Merger Agreement) with UCB S.A. (“ UCB ”).

View on SEC.gov

Browse all material agreements →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-202601

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.